Related Experiment Videos
Serum leptin levels in children receiving long-term carbamazepine
Hüseyin Caksen1, Gülhis Deda, Merih Berberoğlu
1Departments of Pediatrics, Yüzüncü Yil University Faculty of Medicine, Van, Turkey. huseyincaksen@hotmail.com
Insights
Long-term carbamazepine (CBZ) therapy in children with epilepsy did not significantly alter serum leptin levels or body mass index compared to healthy controls. These findings suggest CBZ is not associated with substantial weight gain or altered leptin in pediatric patients.
Area of Science:
- Pediatric Endocrinology
- Neuropharmacology
- Metabolic Research
Background:
- Carbamazepine (CBZ) is a widely used antiepileptic drug.
- Potential metabolic side effects, including weight changes and alterations in appetite-regulating hormones like leptin, warrant investigation.
- Understanding these effects is crucial for managing long-term pediatric epilepsy treatment.
Purpose of the Study:
- To investigate the relationship between long-term carbamazepine (CBZ) therapy and serum leptin levels in children.
- To assess whether CBZ treatment is associated with significant weight gain or altered body mass index (BMI) in pediatric patients.
- To explore any correlation between serum leptin levels and CBZ drug levels.
Main Methods:
- Comparative study involving 14 children on long-term CBZ therapy for epilepsy and 19 healthy children.
- Measurement of serum leptin levels and body mass index (BMI) in both groups.
- Analysis of potential correlations between serum leptin, CBZ levels, and clinical parameters.
Main Results:
- No significant differences were observed in age, sex, BMI, or serum leptin levels between the CBZ-treated group and the healthy control group (p > 0.05).
- Only two patients (14%) in the CBZ group reported overeating and weight gain.
- No significant correlation was found between serum leptin levels and CBZ drug levels (r: 0.48; p > 0.05).
Conclusions:
- Preliminary findings suggest that long-term carbamazepine (CBZ) therapy in children does not lead to significant weight gain or altered serum leptin levels compared to controls.
- The study indicates no direct relationship between serum leptin and CBZ levels in this pediatric cohort.
- Further extensive research is recommended to confirm these observations and elucidate the long-term metabolic effects of CBZ in children.
Abstract:
In this article we studied serum leptin levels in children receiving long-term carbamazepine (CBZ) therapy (mean 3.4 years) to determine whether or not there was a relationship between serum leptin level and CBZ therapy. The study includes 14 patients followed with the diagnosis of epilepsy and treated long term CBZ, and 19 healthy children. Only two (14%) patients complained about overeating and weight gain. We did not find any significant difference for age, sex, body mass index and serum leptin levels between the study and control groups (p > 0.05). If a markedly weight gain was seen in the study group, a higher levels of serum leptin could be expected. Additionally, there was not a relationship between serum leptin and CBZ levels (r: 0.48; p > 0.05). Our preliminary findings showed that long-term use of CBZ did not cause markedly weight gain in childhood and serum leptin levels did not differ from the control subjects. We think that more extensive studies should be performed about this subject.